Virax Biolabs Group Stock (NASDAQ:VRAX)
Previous Close
$1.19
52W Range
$1.14 - $21.75
50D Avg
$2.30
200D Avg
$4.02
Market Cap
$1.60M
Avg Vol (3M)
$386.70K
Beta
1.39
Div Yield
-
VRAX Company Profile
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.